Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Patrice Cacoub (), Mathieu Vautier, A. C. Desbois, David Saadoun () and Zobair Younossi
Additional contact information
Patrice Cacoub: I3 - Immunologie - Immunopathologie - Immunothérapie - UPMC - Université Pierre et Marie Curie - Paris 6 - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique
Mathieu Vautier: I3 - Immunologie - Immunopathologie - Immunothérapie - UPMC - Université Pierre et Marie Curie - Paris 6 - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique
A. C. Desbois: CHU Pitié-Salpêtrière [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université, I3 - Immunologie - Immunopathologie - Immunothérapie - UPMC - Université Pierre et Marie Curie - Paris 6 - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique
David Saadoun: I3 - Immunologie - Immunopathologie - Immunothérapie - UPMC - Université Pierre et Marie Curie - Paris 6 - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique
Zobair Younossi: Inova Fairfax Hospital - Center for Integrated Research

Post-Print from HAL

Abstract: Background: The economic impact of extrahepatic manifestations of hepatitis C virus (HCV) infection remains unknown for France. Aim: To estimate the prevalence of extrahepatic manifestations of HCV and the direct medical costs associated with them. Methods: Estimates of 13 extrahepatic manifestations prevalence were obtained from (1) a retrospective data analysis of HCV-infected patients in a specialised centre and the baseline prevalence in the general French population and (2) an international systematic review. Per-patient-per-year costs to treat these manifestations were obtained from the literature, national databases or expert opinion. The impact of achieving HCV cure after anti-viral therapy was applied to the French healthcare costs. Results: Using approach (1), increased prevalence rates in HCV patients compared to the general population were observed for most extrahepatic manifestations. The mean per-patient-per-year cost of these manifestations in the tertiary centre was 3296 € [95% CI 1829; 5540]. In France, HCV-extrahepatic manifestations amounted to a total cost of 215 million (M) € per year [144; 299]. Using approach (2), the mean per-patient-per-year cost was estimated to be 1117 €. The estimated total cost reduction in France associated with HCV cure was 13.9 M€ for diabetes, 8.6 M€ for cryoglobulinemia vasculitis, 6.7 M€ for myocardial infarction, 2.4 M€ for end-stage renal disease and 1.4 M€ for stroke. Conclusion: Extrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti-viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.

Date: 2017
New Economics Papers: this item is included in nep-hea
Note: View the original document on HAL open archive server: https://hal.sorbonne-universite.fr/hal-01628353
References: Add references at CitEc
Citations:

Published in Alimentary Pharmacology & Therapeutics (Suppl), 2017, ⟨10.1111/apt.14382⟩

Downloads: (external link)
https://hal.sorbonne-universite.fr/hal-01628353/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01628353

DOI: 10.1111/apt.14382

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().